Improving Sleep Diagnostics By Revolutionizing Sleep Monitoring
April 29th 2019Onera’s co-founder and chief medical officer, and the associate professor at John’s Hopkins University spoke about the plans for recently raised Series A funding and how a newly developed patch system could alter the diagnostics of sleep medicine.
Biofluid Biomarkers Hold Promise for the Future of Huntington Disease
April 29th 2019Currently, there are no disease-modifying medications for Huntington disease and few interventions available to effectively alleviate symptoms, while the lack of indicators of pathobiological processes at the molecular level has limited the ability to prove efficacy and safety in clinical trials.
Approaching Lacunar Stroke and Dementia With a Dual Treatment Regimen
April 28th 2019The chair of Applied Neuroimaging and head of Neuroimaging Sciences and Edinburgh Imaging at the University of Edinburgh spoke about what the physician community needs to know about utilizing isosorbide mononitrate and cilostazol for lacunar stroke.
Creativity, Persistence Are Key to Advancing the Approach to MS Symptom Management
April 27th 2019Although highly efficacious DMTs have improved outcomes for a growing number of patients, the majority of people with MS are still subjected to the day-to-day consequences of the disease’s symptoms, which often have a more debilitating effect on the patient than the disease itself.
Cilostazol, Isosorbide Mononitrate Combination Well-Tolerated in Lacunar Stroke
April 26th 2019An escalating, combination dose of isosorbide mononitrate and cilostazol was shown to be well tolerated, with 72% of patients achieving full or ≥50% partial doses, the primary outcome, by the end of the 8-week treatment period.
FDA Issues Stroke Risk Reminder for Improper Use of Wingspan Stent System
April 26th 2019The FDA issued a reminder that improper use of the Stryker Wingspan Stent System can result in an increased risk for stroke or mortality. The agency advises against using the system when the onset of symptoms is within 7 days or less of treatment or for the treatment of transient ischemic attacks.
NuPlasma Young Blood Plasma Shows Positive 3-Month Data in Parkinson Disease
April 25th 2019NuPlasma yFFP was associated with improvements in complications of therapy, motor examination scores, mentation, behavior, and mood, and in activities of daily living in patients with Parkinson disease.